

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application Number:	10/509,268
Applicant:	BERG, Stefan, <i>et al.</i>
Filed:	09/27/2004
TC/A.U.:	1626
Examiner:	CHUNG, Susannah Lee

AstraZeneca Docket No.	100632-1P US
Customer No.	22466

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

The owner, AstraZeneca AB, of 100 percent interest in the instant application to obviate a double-patenting rejection hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application that would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/572,778, filed on March 21, 2006, as such term is defined in 35 U.S.C. §§ 154 to 156 and 173, and as the term of any patent granted on said pending reference Application may be shortened by any terminal disclaimer filed prior to the grant of any patent granted on said pending reference Application.

The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on said pending reference Application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent granted on said pending reference Application, as presently shortened by any terminal disclaimer, in the event that any patent granted on said pending reference Application later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or in part, is terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated before the expiration of its full statutory term as presently shortened by any terminal disclaimer.

In accordance with the fee schedule in 37 C.F.R. § 1.20(d), the required fee is to be charged to Deposit Account No. 26-0166. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should also be charged to said Deposit Account.

Respectfully submitted,

Dated: February 4, 2008

By: / Kenneth F. Mitchell /
Kenneth F. Mitchell, Ph.D., J.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466